Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study.
Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study.
复制标题
锂盐和三环类药物增强氟西汀治疗顽固性重度抑郁症:一项双盲对照研究。
DOI:
10.1176/ajp.151.9.1372
复制
发表时间:
1994
期刊:
影响因子:
--
通讯作者:
Quitkin Fm
中科院分区:
文献类型:
--
作者:
M. Fava;J. Rosenbaum;McGrath Pj;Stewart Jw;J. Amsterdam;Quitkin Fm
Forty-one patients who had failed to respond to 8 weeks of treatment with 20 mg of fluoxetine were randomly assigned to one of three treatments for 4 weeks: 40-60 mg/day of fluoxetine, 20 mg/day of fluoxetine plus 25-50 mg/day of desipramine, and 20 mg/day of fluoxetine plus 300-600 mg/day of lithium. Patients treated with high-dose fluoxetine (N = 15) did significantly better than patients treated with fluoxetine plus lithium (N = 14) and those treated with fluoxetine plus desipramine (N = 12). High-dose fluoxetine was the most effective treatment among partial responders to previous treatment, but high-dose fluoxetine and fluoxetine plus lithium were the most effective treatments among nonresponders.